Field Medical and Kardium—two companies developing pulsed field ablation (PFA) systems for the treatment of heart rhythm disorders—have secured funding rounds worth US$35 million and US$250 million, respectively.
Earlier this month, Field Medical announced the close of an oversubscribed US$35 million Series B financing round, co-led by BioStar Capital and Cue Growth with participation from existing strategic investors.
This funding will be used to advance development of the company’s FieldForce ablation system—a next-generation PFA technology designed for transmural lesion creation that offers a novel approach to ventricular tachycardia (VT) ablation—and support initiation of its pivotal VERITAS trial.
“VT is among the most underpenetrated segments in electrophysiology, yet physicians still lack the tools they need,” said Steven Mickelsen, founder and chief executive officer (CEO) of Field Medical. “What is exciting is how VT is mirroring the early days of the AF [atrial fibrillation] market—strong clinical demand unmet by existing technology. We are poised to unlock this opportunity with our next-generation therapy built for speed, precision and real clinical progress, advancing toward pivotal readiness and redefining what is possible in VT care for high-risk patients.”
In addition, Kardium recently announced that it has raised US$250 million via a new, oversubscribed financing round led by new investors including Janus Henderson Investors, Qatar Investment Authority (QIA), MMCAP, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital, with participation from existing investors.
This funding will enable Kardium to pursue regulatory approvals for the Globe system—a PFA technology intended to treat AF by enabling pulmonary vein isolation (PVI), high-definition mapping, and the ability to ablate “anywhere in the atrium”, via a single catheter. The financing round will also bolster Kardium’s efforts to expand its manufacturing facilities and production capacity; conduct further clinical research on additional applications and expanded indications for the Globe system; and establish a clinical support and commercial team in preparation for the anticipated commercial launch of the system later this year.
“We’re thrilled to have secured this transformational financing with a world-class syndicate of investors,” said Kevin Chaplin, CEO of Kardium. “This funding enables us to move ahead with the commercial launch of the Globe system by expanding our manufacturing capabilities and building a strong commercial team. Everyone at Kardium is energised by the opportunity to bring the Globe system to market and help improve the lives of millions of patients worldwide suffering from AF.”
